Multi-detection Method Compatible Negative CTC Rapid Identification Technology Based On Microfluidic Chip

In recent decades,due to the continuous deterioration of the human living environment and the emergence of problems such as food safety and aging,malignant tumors have rapidly risen to become one of the leading causes of death for humans worldwide,and most of the cancer patients' disease is due to the disease Caused by untimely diagnosis and the spread of tumor cells.Circulating Tomor cells(CTCs)refer to tumor cells that enter the human peripheral blood when the tumor is shed.Because they flow with the blood,they are called circulating tumor cells.Many studies have shown that the detection of circulating tumor cells has important clinical significance,such as judging the patient's condition,prognostic treatment of the patient,and formulating a targeted treatment plan.However,because the content of CTC is scarce in patients,enriching CTC is a problem that must be faced in the detection process.At the same time,mutations in tumor cells during metastasis will cause changes in cell surface markers,and will also affect tumor cells.Enrichment has a greater impact,and relies too much on manual operation during the detection process,which will cause a large operational error and affect the final detection result.For this series of problems in identifying CTCs,this paper proposes to design a rapid detection technology for negative CTCs compatible with multiple detection methods based on microfluidic chips.This design is aimed at sample processing,CTC enrichment,and antibody specificity during CTC detection.A series of investigations have been conducted on issues such as sexual identification.The main work of this subject is as follows:First,based on the morphological characteristics of whole blood blood cells,a set of beveled microfluidic chips based on the size separation method was designed and used to perform CTC enrichment processing on patient whole blood samples.A set of semi-automatic experimental devices can be used to realize the semi-automatic control of sample injection and subsequent antibody recognition in the chip;CTC enrichment was performed on the basis of the microfluidic chip and the semi-automatic experimental device to prove the feasibility of the project scheme.Secondly,because the size screening function of the chip can only perform preliminary screening of cells in the blood,and cannot effectively distinguish leukocytes close to CTC in size,the cells captured by the chip need to be specifically identified.In this experiment,CD45 was carried The immune microspheres of the antibody specifically recognize the cells in the chip.Because the CD45 antigen exists only on the surface of leukocytes,the immunomicrosphereswill specifically bind to leukocytes,which can cause them to be clearly distinguished from CTC in the bright field.Identification of CTC.Finally,the experimental results are specifically quantified by measuring the integrated optical density value on the cell surface,and the image of the experimental result is processed by using IPP(Image-Pro Plus)software,and the integrated optical density value on the cell surface is calculated to realize the CTC identification.Provide data support.This topic applies microfluidic chip technology,immune recognition technology,and optical density detection technology to each step of CTC detection,which simplifies the entire experimental process of CTC detection,improves the degree of automation and detection efficiency of CTC detection,and saves a lot of Experimental consumables have certain clinical application value.